NASDAQ: TARSTarsus Pharmaceuticals Inc Stock
$49.25-0.14 (-0.28%)
Updated Apr 17, 2025
TARS Price
$49.25
Fair Value Price
-$24.06
Market Cap
$1.89B
52 Week Low
$20.08
52 Week High
$57.28
P/E
-16.04x
P/B
8.42x
P/S
11.38x
PEG
N/A
Dividend Yield
N/A
Revenue
$182.95M
Earnings
-$115.55M
Gross Margin
93%
Operating Margin
-58.87%
Profit Margin
-63.2%
Debt to Equity
0.68
Operating Cash Flow
-$83M
Beta
0.93
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
TARS Overview
Tarsus Pharmaceuticals Incorporated is a clinical-stage biopharmaceutical company that develops and commercializes ophthalmic and other therapies. The company's lead product candidate is TP-03, in a Phase III clinical trial, for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals was incorporated in 2016 and is headquartered in Irvine, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TARS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TARS
Ranked#42 of 463
Ranked#42 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important TARS news, forecast changes, insider trades & much more!
TARS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TARS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TARS ($49.25) is overvalued by 304.73% relative to our estimate of its Fair Value price of -$24.06 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TARS ($49.25) is not significantly undervalued (304.73%) relative to our estimate of its Fair Value price of -$24.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TARS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TARS due diligence checks available for Premium users.
Valuation
TARS fair value
Fair Value of TARS stock based on Discounted Cash Flow (DCF)
Price
$49.25
Fair Value
-$24.06
Undervalued by
304.73%
TARS ($49.25) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TARS ($49.25) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TARS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TARS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-16.04x
Industry
-177.72x
Market
27.98x
TARS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.42x
Industry
4.05x
TARS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TARS's financial health
Profit margin
Revenue
$66.4M
Net Income
-$23.1M
Profit Margin
-34.8%
TARS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TARS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$377.0M
Liabilities
$152.5M
Debt to equity
0.68
TARS's short-term assets ($356.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TARS's short-term assets ($356.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TARS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TARS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.2M
Investing
-$59.6M
Financing
$2.9M
TARS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TARS vs Biotech Stocks
Tarsus Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.